The case for early ADME-TOX Drug discovery seminar programme launched by CXR Biosciences

29 July 2003. A series of half-day seminars is being organised by innovative pre-clinical specialists, CXR Biosciences (Dundee, Scotland) and sponsored by Bio-Dundee (part of the Biotech Scotland initiative). These will outline how and why integrating the new generation of faster, more relevant ADME-TOX models into early-stage lead selection and screening makes scientific and commercial sense for all drug discovery companies.

Most ‘big pharma’ already considers early-stage ADME-TOX crucial to their in-house discovery programmes. Naturally, they are looking for the same data from potential partners.

The first seminars will take place on 16, 17 and 18 September 2003 in London, Oxford and Cambridge, respectively. Participants will hear the founding CXR scientists and a keynote speaker from a major pharmaceutical company, in a programme designed to stimulate and inform senior drug discovery scientists and managers from biotech and ‘emerging pharma’ in this increasingly important area.  

To find out more or to register to attend, please email: seminars@cxrbiosciences.com

Text ends

About CXR Biosciences:

CXR is a Dundee based company focused on applying the latest molecular and genetic techniques to accelerate drug development, reduce product attrition and “rescue”, where appropriate, molecules with unexplained toxicological observations. This is achieved by developing innovative approaches to improve the predictability and relevance to man of preclinical models. The company occupies a state of the art laboratory facility in the Dundee Technopole in Scotland and is built on the decades of experience in preclinical development of its founders, Professor Roland Wolf, and Dr. Cliff Elcombe, of Dundee University. CXR has several research collaborations with pharmaceutical and biotechnology companies to provide novel models, assays and screens for use in preclinical development. The company also provides specialist contract services in many areas of preclinical development.

About Bio-Dundee:

Working as part of the Biotech Scotland initiative, Bio-Dundee promotes supports and stimulates the partnership between public, private and academic organisations in Dundee’s fast growing life science sector.

Press information:                Please send enquires to:

Richard Kent                        Fiona Adair

Kapler Communications Ltd     Business Development Director

Suite 2, Cressner House         CXR Biosciences

12 Huntingdon Street               James Lindsay Place

St Neots                                 Dundee Technoploe

Cambridgeshire                      Dundee

PE19 1BD                              DD1 5JJ

Tel: +44 (0) 1480 471117           Tel: +44 (0) 1382 432163

Email: richard@kapleronline.com           Email: FionaAdair@cxrbiosciences.com